Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-18
2011-01-18
Wang, Shengjun (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07872035
ABSTRACT:
The present invention relates to the use of an angiotensin II type 1 receptor antagonist of the general formula (I) in the manufacture of a medicament for the prophylactic and/or therapeutic treatment of a vascular headache condition such as migraine, in a subject suffering from, or susceptible to, such a vascular headache condition. A further aspect of the invention is a pharmaceutical formulation useful in any one of said vascular headache conditions, as well as a method of treatment thereof.
REFERENCES:
patent: 5196444 (1993-03-01), Naka et al.
patent: 5214153 (1993-05-01), Chen et al.
patent: 5703110 (1997-12-01), Naka et al.
patent: 456510 (1991-11-01), None
patent: 510813 (1992-10-01), None
patent: 513979 (1992-11-01), None
patent: 0456136 (2002-03-01), None
Doctor's Guide “Central Brain sites hold the key to effective migraine remedies,” 1997, http://www.pslgroup.com/dg/394BA.htm.
Hansson et al. “Headache in Mild-to-Moderate Hypertension and its Reduction by Irbesartan Therapy”, Arch. Intern. Med., 2000, 160: 1654-1658.
Wolff, “Headache and Other Head Pain,” New York: Oxford University Press, 1963.
Sicuteri, “Substance P and Enkephalins: A Creditable Tandem in the Pathophysiology of Cluster Headache and Migraine”, Advances in Experimental Medicine & Biology, 1986, 198, Pt B:145-52.
Hannington et al., “Migraine: A Platelet Disorder”, Lancet, 1981, 2; 720-3.
Lance et al., “Brainstem Influences on the Cephalic Circulation: Experimental Data From Cat and Monkey of Relevance to the Mechanism of Migraine,” Headache, 1983, 23:258-65.
Welch, “Migraine. A Biobehavioral Disorder”, Archives of Neurology, 1987, 44(3):323-7.
Olesen, “Clinical and Pathophysiological Observations in Migraine and Tension-Type Headache Explained by Integration of Vascular, Supraspinal and Myofascial Inputs”, Pain, 1991, 46(2): 125-32.
Stewart et al., “Prevalence of Migraine Headache in the United States: Relation to Age, Income, Race, and Other Sociodemographic Factors”, JAMA, 1992, 267:64-9.
Lipton et al., “Undiagnosed Migraine Headaches. A Comparison of Sympton-Based and Reported Physician Diagnosis”, Archives of Internal Medicine, 1992, 152(6): 1273-8.
Celentano et al., “Medication Use and Disability Among Migraineurs: A National Probability Sample Survey”, Headache, 1992, 32(5):223-8.
J. Culman et al., “The renin-angiotensin system in the brain: possible therapeutic implicatiotis for AT1-receptor blockers”, Journal of Human Hypertension (2002), 16, S64-S70.
Brainard, M.D., John B. “Angiotensin and Aldosterone Elevation in Salt-induced Migraine”, Headaches 21:222-226,1981.
Yumiko Shibouta et al., “Pharmacological Profile of a Highly Potent and Long-Acting Angiotensin II Receptor Anatgonist . . . ”, The Journal of Pharmacology and Experimental Therapeutics, 1993, vol. 266, No. 1, 114-120.
Keifu Song et al. “Inhibition of the Angiotensin II Type 1 Receptor by TCV:116: Quantitation by In Vitro Autoradiography”, Japanese Journal of Pharmacology, 1999, vol. 79, No. 2, 131-139.
Y. Nishimura et al., “The angiotensin AT1receptor antagonist CV-11974 regulates cerebral blood flow and brain angiotensin AT1receptor expression”, Basic Research in Cardiology, 1998, vol. 93, suppl. 2, 63-68.
William I. Bender, “ACE Inhibitors for Prophylaxis of Migraine Headaches”, Headache, 1995, vol. 35, No. 8, 470-471.
“Renin-Angiotensin System: Possible Role in Headache Mechanism”, Vasoactive Substance Relevant to Migraine, 1975, 90-97.
Astrazeneca AB
Wang Shengjun
White & Case LLP
LandOfFree
Angiotensin II antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Angiotensin II antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Angiotensin II antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2695149